Revolution Medicines, Inc. (RVMD) Q1 2024 Earnings Call Transcript

Revolution Medicines, Inc. (RVMD) Q1 2024 Earnings Call Transcript

Earnings Call Transcripts21:11 ET

Revolution Medicines Q1 2024 GAAP EPS $(0.70) Beats $(0.75) Estimate

Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(0.75) by 6.67 percent.

Benzinga18:21 ET

Revolution Medicines Q1 Net Loss Narrows

Revolution Medicines (RVMD) reported a Q1 net loss Wednesday of $0.70 per share, narrowing from a loss of $0.72 a year earlier. Analysts polled by Capital IQ expected a loss of $0.75. The company did

MT Newswires17:37 ET

Revolution Medicines Reiterates Projected Full Year 2024 GAAP Net Loss To Be $(480)M-$(520)M

Based on the company's current operating plan, the company projects current cash, cash equivalents and marketable securities can fund planned operations into 2027.

Benzinga17:02 ET

Express News | Revolution Medicines Inc: Reiterating Projected 2024 Gaap Net Loss Between $480 Mln and $520 Mln

Reuters16:51 ET

Express News | Revolution Medicines Inc: Total Revenue Was Zero for Quarter Ended March 31 Vs $7.0 Mln

Reuters16:50 ET